Survival of deoxyguanosine-treated fetal thymus allografts is prevented by priming with dendritic cells.
Allogeneic thymus lobes rendered alymphoid by treatment with deoxyguanosine are not rejected in normal mice despite expression of class I and class II MHC antigens on donor cells. The results presented here show that the injection of as few as 10,000 cells from dendritic cell-enriched populations is followed by the rejection of deoxyguanosine-treated grafts. These findings support the notion that treated thymus grafts do not provoke rejection because they lack dendritic cells, which are destroyed by deoxyguanosine.
D000818:Animals; D003713:Dendritic Cells / Q000276:immunology*; D003849:Deoxyguanosine / Q000494:pharmacology*; D006084:Graft Rejection; D006085:Graft Survival / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008815:Mice, Inbred Strains; D013950:Thymus Gland / Q000033:anatomy & histology / Q000637:transplantation*; D014184:Transplantation, Homologous
D003849:Deoxyguanosine